当前位置: 首页 > 期刊 > 《中国药房》 > 202023
编号:13789008
新型降脂药PCSK9抑制剂依洛尤单抗的研究进展(8)
http://www.100md.com 2020年12月1日 《中国药房》 202023
     [31] ZHANG XL,ZHU QQ,ZHU L,et al. Safety and efficacy of anti-PCSK9 antibodies:a meta-analysis of 25 rando- mized,controlled trials[J]. BMC Med,2015. DOI:10. 1186/s12916-015-0358-8.

    [32] GIUGLIANO RP,MACH F,ZAVITZ K,et al. Cognitive function in a randomized trial of evolocumab[J]. N Engl J Med,2017,377(7):633-643.

    [33] GORDON T,KANNEL WB,CASTELLI WP,et al. Lipoproteins,cardiovascular disease,and death:the Framingham study[J]. Arch Intern Med,1981,141(9):1128-1131.

    [34] RUDOLPH AE,SILLESEN H,SIMUNOVIC L,et al. Stroke prevention by aggressive reduction in cholesterol levels (SPARCL) investigators:high-dose atorvastatin after stroke or transient ischemic attack[J]. N Engl J Med,2006,355(54):549-559.

    [35] HEIKKILA P,KAHRI AI,KOVANEN PT,et al. Effects of mevinolin,an inhibitor of cholesterol synthesis,on the morphology and function of differentiating and differen- tiated rat adrenocortical cells in primary culture[J]. Cell Tissue Res,1990,261(1):125-132.

    [36] BLOM DJ,DJEDJOS CS,MONSALVO ML,et al. Effects of evolocumab on vitamin E and steroid hormone levels results from the 52-week,phase 3,double-blind,randomized,placebo-controlled DESCARTES study[J]. Circ Res,2015,117(8):731-741.

    (收稿日期:2020-07-01 修回日期:2020-11-05)

    (編辑:罗 瑞), 百拇医药(刘东华 李祥鹏 徐龙 杨雪 李静 曲海军 邢晓敏 程绍远 张斌 王攀峰 荆凡波)
上一页1 2 3 4 5 6 7 8